© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, review currently available treatment options for acute and chronic GVHD and discuss the management of steroid-refractory disease.
April 13th 2021
Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, provide insight on the nature of graft-vs-host disease (GVHD) and common risk factors for acute and chronic GVHD.
Hematologist-oncologists review the typical presentation and diagnosis of acute and chronic GVHD and define how severity is classified.
April 20th 2021
A discussion on the role of prophylactic therapy for patients after transplant as well as available options for GVHD prophylaxis.
Experts in hematology-oncology share insights on approaching initial treatment and the treatment goals for acute and chronic GVHD.
April 27th 2021
Defining steroid-refractory acute GVHD, treatment options for patients who don’t respond to steroid therapy, and a review of the REACH2 trial.
A review of treatment options for patients with chronic GVHD who don’t respond to steroid therapy and preliminary findings from the phase 3 REACH3 trial.
May 4th 2021
Novel agents in the pipeline for the treatment of acute and chronic GVHD are discussed.
Challenges and unmet needs in steroid-refractory GVHD and advice to community oncologists for the optimal management of disease.